FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Active, not recruiting · NCT06909825 · Registry updated 2026-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Metastatic Castration-resistant Prostate Cancer | Active, not recruiting | Phase 2 | 2026-10-06 | NCT06909825 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Fusion Pharmaceuticals Inc. | 3 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Icon Cancer Centre Kurralta Park | Kurralta Park | Australia | 6 |
| Macquarie University Hospital | Macquarie Park | Australia | 3 |
| Peter MacCallum Cancer Center | Melbourne | Australia | 12 |
| Princess Alexandra Hospital | Woolloongabba | Australia | 106 |